K150304 Cay 1/2



510(k) SUMMARY OF SAFETY AND EFFECTIVENESS INFORMATION

A. Submitter Information:

Submitter's Name:

ConMed Endoscopic Technologies, Inc.

Submitter's Address:

129 Concord Road,

Billerica MA 01821-7031

Contact Person:

Thomas Hirte

Contact Person's Telephone Number:

(978) 964-4252

Contact Person's FAX Number:

(978) 964-4250

B. Device Name:

FXWireTM Advanced Measurement Guidewire

C. Predicate Devices:

XWire[™] Next Generation Guidewire (K011759)

D. Device Description:

The FXWireTM Advanced Measurement Guidewire is a kink resistant metal alloy cored guidewire, which is encapsulated in a PTFE jacket. The guidewire has a flexible radiopaque tip, with a hydrophilic coating for enhanced lubricity. At the distal end of the guidewire, there are painted marker bands beginning at 6cm and extending to 30cm from the distal tip of the guidewire, as well as two radiopaque marker bands placed at 10cm and 15 cm from the distal tip of the guidewire. Additionally, at the proximal end of the guidewire, endoscopic marker bands have been placed beginning at 210cm and extending to 270cm from the distal tip of the guidewire. These marker bands enable endoscopic and fluoroscopic visualization of movement, as well as estimation of stricture length. This guidewire meets the recognized standard for high frequency current leakage (Reference ANSI/AAMI

K150304 Page 20/2

Standard HF 18-1993) when used with a sphinctertome and may be left in place during electrosurgical cutting.

E. Intended Use:

The FXWire Advanced Measurement Guidewire is designed to be used to guide and exchange endoscopic accessories and electrosurgical devices for biliary procedures.

F. Technological Characteristics Summary:

The FXWireTM Advanced Measurement Guidewire device is a kink resistant metal alloy cored guidewire, which is encapsulated in a PTFE jacket. The guidewire has a flexible radiopaque tip, with a hydrophilic coating. At the distal end of the guidewire, there are painted marker bands beginning at 6cm and extending to 30cm from the distal tip of the guidewire, as well as two radiopaque marker bands placed at 10cm and 15 cm from the distal tip of the guidewire. Additionally, at the proximal end of the guidewire, endoscopic marker bands have been placed beginning at 210cm and extending to 270cm from the distal tip of the guidewire.

G. Performance Data:

Design verification data demonstrated that the FXWireTM Advanced Measurement Guidewire meets the same performance requirements and is as safe and effective as the predicate device.



MAR 8 - 2005

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Thomas Hirte, P.E.
Senior Regulatory Affairs Specialist
ConMed® Corporation
ConMed® Endoscopic Technologies, Inc.
129 Concord Road, Building 3
BILLERICA MA 01821

Re: K050304

Trade/Device Name: FXWire™ Advanced Measurement Guidewire

Regulation Number: 21 CFR §876.1500 Regulation Name: Endoscope and accessories

Regulatory Class: II Product Code: 78 KOG Dated: February 3, 2005 Received: February 8, 2005

Dear Mr. Hirte:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the <u>Code of Federal Regulations</u>, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

21 CFR 876.xxxx	(Gastroenterology/Renal/Urology)	240-276 - 0115
21 CFR 884.xxxx	(Obstetrics/Gynecology)	240-276-0115
21 CFR 892.xxxx	(Radiology)	240-276 - 0120
Other	, G27	240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Nancy C. Brogdon

Director, Division of Reproductive, Abdominal, and Radiological Devices

Manay C. brogdon

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Indications for Use Statement

510(k) Number (if known):	TBD K050304	
Device Name:	FXWire TM Advanced M	easurement Guidewire
Indications For Use:	To be used to guide and and electrosurgical device guidewire is indicated for biliary ducts, including least to the second secon	exchange endoscopic accessories ces for biliary procedures. The or selective cannulation of the out not limited to the common bile. ight and left hepatic ducts.
	E BELOW THIS LINE-C IF NEEDED) of CDRH, Office of Dev	CONTINUE ON ANOTHER PAGE ———————————————————————————————————
,		
Prescription Use (Per 21 CFR 801.109)	OR	Over-The-Counter Use (Optional Format 1-2-96)
	Page 16 of 70	(Division Sign-O4) Division of September 48 12050304